Efficacy of Additional Solifenacin Succinate Therapy in Females with Urinary Tract Infection

Document Type: Editorial

Authors

1 Department of Urology, Zahedan University of Medical Sciences, Zahedan-Iran

2 Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran

10.22034/au.2020.227867.1017

Abstract

UTI as urinary tract infection is a collective word for diseases involving any portion of the urinary tract and it's the most common infections in local primary care that has suffered from it by up to 60 percent of females and has at least one symptomatic UTI in a lifetime. UTI happens in both sexes, but for anatomical, hormonal, and pregnancy reasons are more prevalent in females.
UTI can have consequences like kidney infection, infections of the urinary tract, and eventually, toxic septicemia. Increasing drug resistance has made it essential in the experimental field to assess the pattern of antibiotic resistance.
UTI is often confused with wide-spectrum antibiotics, so it is imperative to characterize resistance patterns to enhance in-vitro antibiotic strategies
According to previous studies and research, the use of anticholinergics to relieve UTI symptoms has never been investigated. This research is the first randomized trial of anticholinergic like solifenacin succinate (with a strong affinity for smooth muscle receptors M3) to be used to treat and improve UTI..

Keywords